Boxed Warning: Renal Fibrosis Risk With Use of Gadolinium Contrast Agents

The Food and Drug Administration has requested that a boxed warning explaining the increased risk of nephrogenic systemic fibrosis in patients with renal insufficiency be added to the labels of gadolinium-based contrast agents, according to an alert posted on the agency's MedWatch Web site.